Studying Blood Toxicity in Workers Exposed to Formaldehyde
NCT01547858 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 708
Last updated 2020-11-16
Summary
Background:
\- Formaldehyde has many uses in industry and medicine. However, exposure to formaldehyde has been associated with increased risk for myeloid leukemia. There are still questions about how the chemical reacts with bone marrow to increase this cancer risk. Some smaller studies have looked at how it affects stem cells, which are found in bone marrow. Researchers want to develop a much larger study of workers in China. The study will look at different levels of formaldehyde exposure. It will focus on how the chemical affects the blood cells and bone marrow.
Objectives:
\- To study the effects of formaldehyde exposure on blood cells and bone marrow.
Eligibility:
\- Individuals between 18 and 60 years of age who work in selected factories in Guangdong Province, China.
Design:
* Participants will be screened with a physical exam and medical history. They will also be screened with a work history. Those who have been exposed to benzene, butadiene, styrene, or radiation will not be included.
* Participants will be studied based on their regular formaldehyde exposure level. One-third will be those exposed to more than 1 part per million (ppm) of the chemical. One-third will be those exposed to 0.3 to 1 ppm. A control group will have no exposure to formaldehyde or any other known toxic chemical.
* Participants will provide blood and cheek swab samples. They will also answer questions about their work habits.
* To look at chemical exposure levels, participants will wear a small monitor to work on 3 different days. They may provide additional blood and cell samples as directed.
* No treatment will be provided as part of this study.
Conditions
- Blood
- Chemical Industry
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Qing Lan, M.D. · National Cancer Institute (NCI)
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-02-09
- Primary Completion
- 2013-05-30
- Completion
- 2020-11-12
Countries
- China
More Related Trials
-
Autologous Bone Marrow Stem Cell Transplantation for Critical, Limb-threatening Ischemia
NCT00434616 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Bone Marrow Aspirate Concentrate (BMAC) for Treatment of Critical Limb Ischemia (CLI)
NCT01245335 ·Status: COMPLETED ·Phase: PHASE3
-
Collection of Bone Marrow From Healthy Volunteers and Patients for the Production of Clinical Bone Marrow Stromal Cell (BMSC) Products
NCT01071577 ·Status: TERMINATED
-
Safety and Efficacy of Adipose Derived Stem Cells for Non-Ischemic Congestive Heart Failure
NCT01502501 ·Status: WITHDRAWN ·Phase: NA
-
A Study of Human Allogeneic Bone-marrow-derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Aging Frailty
NCT06070532 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of Adipose Derived Stem Cells for Congestive Heart Failure
NCT01502514 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Phase I/II Safety and Tolerability Dose Escalation Study of Autologous Stem Cells to Patients With Liver Insufficiency
NCT00655707 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Clinical Trial of Autologous Adipose Tissue Derived Stromal Cell Therapy for Ischemic Heart Failure
NCT01709279 ·Status: UNKNOWN ·Phase: NA
-
Mesenchymal Stem Cells in the Treatment of Relapsed/Refractory Severe Acquired Aplastic Anemia
NCT01297972 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Bone Marrow Versus Adipose Autologous Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis
NCT04351932 ·Status: UNKNOWN ·Phase: PHASE3
-
Administration of Adipose-derived Stem Cells (ASC) in Patient With Critical Limb Ischemia.
NCT03968198 ·Status: TERMINATED ·Phase: PHASE2
-
Cell Therapy in Patients With Chronic Ischemic Heart Disease Undergoing Cardiac Surgery
NCT01267331 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Pilot Study Using Placenta Derived Decidual Stromal Cells for Toxicity and Inflammation With Special Focus to the Allogeneic Hematopoietic Cell Transplantation Setting
NCT02175303 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Effect of Exosomes Derived From Red Blood Cell Units on Platelet Function and Blood Coagulation
NCT02594345 ·Status: COMPLETED ·Phase: NA
-
Mesenchymal Stem Cells Therapy for Treatment of Airway Remodeling in Mustard Patients
NCT02749448 ·Status: UNKNOWN ·Phase: PHASE1
-
Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells in Patients With Acute Respiratory Distress Syndrome
NCT05983627 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Autologous Bone Marrow Stem Cell Transfer in Patients With Chronical Critical Limb Ischemia and Diabetic Foot
NCT01232673 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune Thrombocytopenia
NCT04014166 ·Status: COMPLETED ·Phase: NA
-
Procurement of Tissue Samples for Cell Cultures and Analyses
NCT00435877 ·Status: TERMINATED
-
Efficacy and Safety of Umbilical Cord Blood Injection for Critical Limb Ischemia
NCT01019681 ·Status: TERMINATED ·Phase: PHASE1
-
Safety and Efficacy of Autologous Bone Marrow Mononuclear Cells in Patients With Severe Critical Limb Ischemia
NCT01472289 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Umbilical Cord Mesenchymal Stem Cells Injection for Peripheral Arterial Disease
NCT02287831 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Cell Therapy in Chronic Ischemic Heart Disease
NCT00362388 ·Status: TERMINATED ·Phase: PHASE3
-
Mesenchymal Stem/Stromal Cell Therapy in the Treatment of Frailty
NCT04919135 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Quality of Life Improvements With Cord Blood Plasma
NCT03229785 ·Status: UNKNOWN ·Phase: PHASE1